Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 4/20 | 0.38 |
| ▸ | PI4K2B | Q8TCG2 | 4/20 | 0.38 |
| ▸ | PI4K2A | Q9BTU6 | 4/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.38 |
| ▸ | XDH | P47989 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.33 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | HPRT1 | P00492 | 2/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | FBP1 | P09467 | 1/20 | 0.31 |
| ▸ | PNP | P00491 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 2/20 | 0.31 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenine SCHEMBL338435 | 0.93 | PI4KA (0.40) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| Adenine SCHEMBL1035727 | 0.93 | PI4KA (0.40) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| Adenine SCHEMBL2411187 | 0.91 | PI4KA (0.39) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| Adenine SCHEMBL8509836 | 0.91 | PI4KA (0.39) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| Adenine SCHEMBL4908366 | 0.90 | PI4KA (0.38) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| Adenine SCHEMBL385841 | 0.85 | PI4KA (0.45) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| Adenine SCHEMBL3414603 | 0.85 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| Adenine SCHEMBL8110 | 0.85 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| Adenine SCHEMBL3416954 | 0.85 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| Adenine SCHEMBL3413247 | 0.85 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114057816-A | Adenine-rich phosphorothioate oligonucleotide and application thereof in resisting hepatitis virus | 浙江柏拉阿图医药科技有限公司 | 2022-02-18 | — | — | CN | claimed |
| CN-114057816-B | Adenine-enriched phosphorothioate oligonucleotide and application thereof in resisting hepatitis virus | 浙江柏拉阿图医药科技有限公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-114057816-A | Adenine-rich phosphorothioate oligonucleotide and application thereof in resisting hepatitis virus | 浙江柏拉阿图医药科技有限公司 | 2022-02-18 | — | — | CN | disclosed |
| US-9221868-B2 | Uridine di- or tri-phosphate derivatives and uses thereof | BAR-ILAN UNIVERSITY (IL) | 2015-12-29 | — | — | US | disclosed |
| EP-2646449-B1 | URIDINE DI- OR TRI-PHOSPHATE DERIVATIVES AND USES THEREOF | UNIV BAR ILAN (IL) | 2015-08-19 | — | — | EP | disclosed |
| EP-2380897-B1 | RNAi modulation of ApoB and uses thereof | ALNYLAM PHARMACEUTICALS INC (US) | 2015-05-13 | — | — | EP | disclosed |
| EP-2377873-B1 | RNAi modulation of ApoB and uses thereof | ALNYLAM PHARMACEUTICALS INC (US) | 2014-08-20 | — | — | EP | disclosed |
| US-20130324495-A1 | URIDINE DI- OR TRI-PHOSPHATE DERIVATIVES AND USES THEREOF | UNIVERSIDAD COMPLUTENSE DE MADRID (ES) | 2013-12-05 | — | — | US | disclosed |
| EP-2646449-A1 | URIDINE DI- OR TRI-PHOSPHATE DERIVATIVES AND USES THEREOF | Bar-Ilan University (IL) | 2013-10-09 | — | — | EP | disclosed |
| WO-2012073237-A1 | URIDINE DI- OR TRI-PHOSPHATE DERIVATIVES AND USES THEREOF | BAR-ILAN UNIVERSITY (IL) | 2012-06-07 | — | — | WO | disclosed |
| CN-101133074-A | RNAi modulation of APOB and uses thereof | ALNYLAM PHARMACEUTICALS INC (US) | 2008-02-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324495-A1 | URIDINE DI- OR TRI-PHOSPHATE DERIVATIVES AND USES THEREOF | P2RY6, UMPS, P2RY1 | PI4KA 715/4885PI4K2B 924/4885PI4K2A 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.